The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival

Basit Öğe Kaydı
dc.contributor.authorÖven Ustaalioğlu, Bala Başak
dc.contributor.authorBalvan, Özlem
dc.contributor.authorBilici, Ahmet Erkan
dc.contributor.authorDeveli, Ahmet Çağrı
dc.contributor.authorAliustao?lu, Mehmet
dc.contributor.authorVardar, Fugen
dc.contributor.authorErkol, Burçak
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:51:27Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:51:27Z
dc.date.issued2015
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000363023000009
dc.descriptionPubMed ID: 26081286
dc.description.abstractIn the literature, small number of study has addressed time of recurrence in breast cancer. We analyzed clinicopathological factors predicting early or late recurrence in breast cancer patients and also prognostic factors related with recurrence-free survival (RFS) in recurrent patients. We evaluated retrospectively 1980 breast cancer patients. Relapsed was defined as early if it was occured first 5 year of follow-up (Group 1) and late if it was occured after 5 years (Group 2). The clinicopathological factors were compared in respect of time of recurrence. The prognostic factors were evaluated using univariate and multivariate analyses. Recurrence wase detected in 141 patient during follow-up. Tumors recurred after 5 years more likely to have lower stage (p = 0.05), tumors without lymphovascular invasion (LVI) (p < 0.001) and perineural invasion (PNI) (p = 0.01), and also HER2 negative (p < 0.001). The median RFS time and 5 years RFS rates were 42.9 months and 31.9 %, respectively. LVI (p = 0.01), PNI (p = 0.03), HER2 (p = 0.003), progesterone receptor (PR) (p = 0.04), the presence of neoadjuvant chemotherapy (p = 0.003), adjuvant hormonotherapy (p = 0.05) were found to be related with RFS. Axillary lymph node metastasis (p = 0.05) and the presence of PNI (p = 0.009) were poor prognostic factors for early recurrent group. PR-positive tumors (p = 0.001) and luminal subtypes (p = 0.03) had instances of late recurrences significantly. Clinicopathological factors predicting the recurrence time in breast cancer were important to modify adjuvant therapy.
dc.identifier.citationÖven Ustaalioğlu, B. B., Balvan, Ö., Bilici, A. E., Develi, A. Ç., Aliustao?lu, M., Vardar, F. ve Erkol, B. (2015). The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival. Clinical and Translational Oncology, 17(11), 895-902. https://dx.doi.org/10.1007/s12094-015-1323-x
dc.identifier.doi10.1007/s12094-015-1323-x
dc.identifier.endpage902
dc.identifier.issn1699-048X
dc.identifier.issn1699-3055
dc.identifier.issue11
dc.identifier.scopusqualityQ2
dc.identifier.startpage895
dc.identifier.urihttps://dx.doi.org/10.1007/s12094-015-1323-x
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2220
dc.identifier.volume17
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer-Verlag
dc.relation.ispartofClinical and Translational Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectRecurrence
dc.subjectBreast Cancer
dc.subjectLate Recurrence
dc.subjectRecurrence-Free Survival
dc.titleThe differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
bilici, ahmet-2015.pdf
Boyut:
357.45 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu